Detailed price information for Zai Lab Ltd ADR (ZLAB-Q) from The Globe and Mail including charting and trades.

A 50-year-old man presented with dysphagia and proximal muscle weakness. He was diagnosed with immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle. After ...

Description of Case: A 62-year-old male with a past medical history of chronic kidney disease stage 4, hyperlipidemia, and lacunar stroke presented with a 1-month history of worsening painless ...

The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated diseases, today ...

Researchers at Cincinnati Children's Hospital Medical Center in collaboration with Roche, have developed a next-generation human liver organoid microarray platform that could help predict which drugs ...

Monte Rosa Therapeutics Inc., a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, has agreed to collaborate with Novartis to develop novel degraders ...

Objective The association of immune-mediated thrombotic thrombocytopenic purpura (iTTP) and SLE was previously described, but patients with iTTP with coexistent SLE remain poorly characterised.

Objective: Immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) represent distinct subtypes of idiopathic inflammatory myopathies (IIMs). While both conditions share clinical ...